EarningsQ2 2026 Earnings Report
MX:ARDX Q2 2026 EPS Results
Actual EPS-$1.27
Consensus EPS-$1.18
Beat/MissMissed by -$0.09
One Year Ago EPS-$1.45
MX:ARDX Q2 2026 Revenue Results
Actual Revenue$2.19B
Expected Revenue$2.19B
Beat/MissMissed by -$2.86M
YoY Revenue Growth+23.77%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:ARDX Upcoming Earnings
Ardelyx's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ARDX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a predominantly constructive commercial and financial picture — record quarterly revenue, double-digit year-over-year growth for both marketed products, improving losses and a pathway to profitability in 2027 — but is tempered by material payer-access headwinds that slowed new patient starts for IBSRELA, a lowered near-term guidance for IBSRELA, increased operating costs to address access challenges, and pulled longer-range XPHOZAH guidance pending regulatory/market clarity. Management has taken proactive remediation steps (IPN, enlarged FRM team, expanded sales force), retains confidence in long-term potential (including $1 billion IBSRELA ambition and tenapanor IP), and maintains solid liquidity, resulting in a net-positive but cautious outlook.Company Guidance
Record Quarterly Revenue
Total product revenue of $118.0 million in Q2 2026, up 31% year-over-year — the largest quarterly revenue in company history.
IBSRELA Strong Growth
IBSRELA revenue of $86.2 million in Q2 2026, up 33% year-over-year; management cites highest-demand quarter to date and continued physician adoption.
XPHOZAH Momentum
XPHOZAH revenue of $31.9 million in Q2 2026, up 27% year-over-year; total dispenses increased 33% and paid prescriptions rose 25% versus Q2 2025, with highest total writers and prescriptions per writer since Q1 2025.
Improving Profitability Trend
Net loss narrowed to $16.7 million in Q2 2026 from $19.1 million in Q2 2025; management reiterates expectation to be income positive (profitable) in 2027.
Strengthened Commercial Capabilities
Commercial investments: doubled field reimbursement team in H1 2026 and expanded sales force to 144 representatives to increase provider engagement and drive adoption.
Patient Access and Fulfillment Initiatives
IBSRELA Pharmacy Network (IPN) and FRM deployment show improved fulfillment metrics: prescriptions routed through IPN yield faster fills, higher fulfillment rates and approximately 1 additional refill per patient per year.
Solid Balance Sheet and Liquidity
Cash, cash equivalents and short-term investments of $281.8 million at quarter end; management drew $50 million from existing SLR arrangement to enhance flexibility.
Pipeline and IP Position
Advancing tenapanor (ACCEL Phase III for CIC) with enrollment on track and building a robust patent estate anchored by the '299 patent (patent protection referenced through 2042 potential runway).
Disciplined Cost Management and Updated OPEX Target
Company revised 2026 OPEX guidance to be below $500 million reflecting proactive spending management after revenue guidance update.
MX:ARDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed